Genomics plc is a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. Genomics plc uses large-scale genetic information to realise preventative medicine, precision healthcare and improve drug discovery. Backed by some of the leading investors in life sciences, Genomics has an expert cross-disciplinary team of more than 100 people in the UK and the US.
Our therapeutics team applies its deep understanding of human genetics to R&D for the discovery and validation of new drug targets. Our engines and analytics enable better target identification and characterisation, making efficient, tailored, and safe drug discovery a reality.
Every individual carries a unique set of genetic variants. Many of these variants change aspects of our biology including how drugs perform in the body. Looking at individuals who happen to carry genetic variants which affect the same part of our biology as the drug offers insights into human biology, over and above those provided by model systems.